<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03273296</url>
  </required_header>
  <id_info>
    <org_study_id>1341/6.00.00/2017</org_study_id>
    <nct_id>NCT03273296</nct_id>
  </id_info>
  <brief_title>Effect of Antibiotics on Gut Microbiome and Plasma Metabolome</brief_title>
  <official_title>Effect of Antibiotics on Gut Microbiome and Plasma Metabolome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute for Health and Welfare, Finland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute for Health and Welfare, Finland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In recent years it has been observed that the gut microbiome can produce metabolites into
      systemic circulation and thus have important health effects even outside the gastrointestinal
      system. These metabolites may play a role in the pathogenesis of common public health
      problems such as diabetes, obesity and cardiovascular disorders. Modern techniques of mass
      spectrometry-based metabolomics from peripheral blood and gut metagenome sequencing now
      enable detailed examination of these processes. Using samples from the FINRISK 2002 cohort,
      collected by the National Institute for Health and Welfare, we are currently determining the
      gut microbiome and plasma metabolome from &gt; 7000 participants with 15 years of follow-up for
      various health outcomes. This is one of the largest materials of its kind world-wide. The
      design does not, however, allow us to draw causal conclusions on the roles of gut bacteria in
      the composition of plasma metabolome. To enable conclusions which go beyond statistical
      associations, we now propose an extension to the FINRISK 2002 study, where we alter the gut
      bacteriome with a short course of antibiotics and then examine whether a change in plasma
      metabolomics profile will follow. At the same time the trial will give important novel
      information about the effects of commonly used antibiotics on gut bacteriome and on general
      health.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2017</start_date>
  <completion_date type="Actual">December 15, 2017</completion_date>
  <primary_completion_date type="Actual">December 15, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiome</measure>
    <time_frame>Baseline: 0 days; repeat assessments 2 days and 28 days after end of antibiotics.</time_frame>
    <description>Change in gut microbiome from baseline to repeat assessments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolome</measure>
    <time_frame>Baseline: 0 days; repeat assessments 2 days and 28 days after end of antibiotics.</time_frame>
    <description>Change in circulating metabolome from baseline to repeat assessments.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Microbial Colonization</condition>
  <arm_group>
    <arm_group_label>Amoxicillin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Amoxicillin (po) 500 mg x 3 per day for 3 days.</description>
    <arm_group_label>Amoxicillin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin (po) 500 mg x 1 on day 1, 250 mg x 1 on day 2, and 250 mg x 1 on day 3.</description>
    <arm_group_label>Azithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Vancomycin (po) 125 mg x 4 per day for 3 days.</description>
    <arm_group_label>Vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior participation in the FINRISK 2002 survey and current residence in Helsinki
             metropolitan area.

          -  Age range 40-74 years among men and 50-74 years among women.

        Exclusion Criteria:

          -  Known allergy to any antibiotic

          -  A course of antibiotic during the past year

          -  Acute infection

          -  Any major illness (history of myocardial infarction, stroke, diabetes, liver or kidney
             disease, cancer, psychiatric disease). Uncomplicated hypertension is allowed.
             Likewise, statin treatment and women's hormone replacement therapy are allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Perola, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute for Health and Welfare, Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute for Health and Welfare</name>
      <address>
        <city>Helsinki</city>
        <zip>00271</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2017</study_first_submitted>
  <study_first_submitted_qc>September 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2017</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microbiota</keyword>
  <keyword>metabolize</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

